


PHARMACEUTICAL 2017

MANNKIND CORP Rank 25 of 313





PHARMACEUTICAL 2017



MANNKIND CORP Rank 25 of 313

The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 632% points. The greatest weakness of MANNKIND CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 240% points.

The company's Economic Capital Ratio, given in the ranking table, is 155%, being 572% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	77,488
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	92,051
Liabilities, Non-Current	0
Other Assets	648
Other Compr. Net Income	-4.0
Other Expenses	45,653
Other Liabilities	198,605
Other Net Income	58,404
Property and Equipment	28,927
Research and Development	14,917
Revenues	174,758
Selling, General and Administrative Expense	46,928

Output Variable	Value in 1000 USD
Assets	107,063
Liabilities	290,656
Expenses	107,498
Stockholders Equity	-183,593
Net Income	125,664
Comprehensive Net Income	125,662
Economic Capital Ratio	155%